Semaglutide as adjunct to closed-loop therapy in Type 1 Diabetes: A double-blind, crossover RCT

Managing Type 1 Diabetes (T1D) is complex, requiring precise insulin delivery to maintain glycemic control and prevent complications. While closed-loop insulin delivery systems (artificial pancreas) have significantly improved glucose management, challenges like post-prandial hyperglycemia and weight gain can persist. GLP-1 receptor agonists (GLP-1RAs) like semaglutide are well-established for Type 2 Diabetes due to their glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay, which can reduce glycemic variability and promote weight loss. This study explores if these benefits extend to T1D patients already on advanced insulin therapy.

This was a double-blind, crossover, randomized controlled trial (NCT05205928) with 28 participants with Type 1 Diabetes. Participants received weekly subcutaneous semaglutide (dose incrementally increased) or placebo for 11 weeks alongside their usual insulin therapy, followed by 4 weeks of closed-loop pump therapy while continuing the blinded drug. After a 2-week washout, participants crossed over to the other treatment arm. The primary endpoint, though not explicitly stated in the provided abstract, would typically involve glycemic outcomes such as HbA1c, time in range, or glucose variability during the closed-loop phase, along with safety and tolerability.

This clinical trial is listed as COMPLETED, but the provided abstract does not contain any results or findings. Therefore, specific data on the efficacy or safety of semaglutide as an adjunct to closed-loop therapy in Type 1 Diabetes patients cannot be reported at this time. The study aimed to assess glycemic outcomes, anthropometric changes, and side effects. No statistical values, percentages, or p-values are available from the provided record.